May 2026 Research Update

This month added a clearer real-world picture of how VEXAS is treated over time: steroids often bring fast symptom relief, but many people need ongoing doses to prevent flares, and treatment plans vary widely. Across cohorts, hypomethylating agents (for example, azacitidine, a bone-marrow focused drug used in MDS) were reported to act more gradually and, in some patients, to provide more sustained control. These studies also connected certain clinical features, like gastrointestinal involvement and whether a person achieves a response, with differences in outcomes, although follow-up was still limited. [1] [2]

In a Spanish multicenter cohort of 40 men with genetically confirmed VEXAS, corticosteroids were described as producing rapid initial improvement but with frequent difficulty tapering and steroid dependence. In the same cohort, hypomethylating agents were reported to show gradual, sustained improvements, with an overall response reported at 12 months, although many treatment lines were stopped for lack of benefit or toxicity. The study also reported that gastrointestinal involvement signaled worse prognosis, while achieving a clinical or lab response was linked with better survival within the cohort. [1]

A small French pilot study focused on how steroid dose related to day-to-day disease control in 12 men by reconstructing many treatment periods over time. Higher steroid doses were linked to lower measured disease activity and lower flare risk in their analyses, and the authors reported exploratory dose thresholds around 15 mg/day (and 0.2 mg/kg/day) that may separate higher from lower flare risk. The same study reported substantial steroid-related complications in this group, including severe infections and metabolic and bone effects, reinforcing why researchers are trying to understand dose patterns rather than assuming one fixed approach fits everyone. [2]

For patients and caregivers, these reports mainly add context about what people with VEXAS often experience in routine care: quick improvement on steroids can coexist with trouble reducing the dose without symptoms returning, and some centers report longer-lasting control with hypomethylating agents, especially when VEXAS overlaps with bone marrow disease like MDS. The evidence here is observational, so it cannot prove one treatment is best, but it helps clarify why many patients move through several treatment attempts and why both inflammation and blood counts are followed closely over time. What remains uncertain is which patients are most likely to benefit from each approach, and whether the steroid dose thresholds seen in the small pilot study will hold up in larger studies. [1] [2]

This month sharpened the message that where you look strongly affects how often VEXAS is found. When researchers tested a selected group of older men with Sweet syndrome, they identified VEXAS in a meaningful portion, suggesting some skin-first inflammatory presentations may hide an underlying UBA1 mutation. In contrast, a targeted screen of a broader MDS population did not detect the usual high-level VEXAS mutations with the method used, raising the possibility that common VEXAS mutations may be uncommon in unselected MDS cohorts or may require more sensitive testing to detect. [3] [4]

In a single-center Sweet syndrome cohort, VEXAS was confirmed in 3 of 10 higher-risk patients (men over 50) tested, and all VEXAS-positive patients carried the same UBA1 variant (p.Met41Leu). The VEXAS-positive patients more often had macrocytic anemia and had multisystem inflammatory features, and skin symptoms came before the blood disorder in these cases. The study also reported longer survival after the first skin presentation for the VEXAS-positive group than for the VEXAS-negative group in this small cohort. [3]

In a separate cross-sectional screen of 149 people with MDS, the researchers did not find canonical UBA1 mutations at high variant allele frequency using their ARMS-PCR approach on bone marrow DNA. They also reported computer-based protein interaction results linking UBA1 to the NLRP3 inflammasome, a pathway involved in inflammatory cell death, as a possible biological connection worth further work. The authors emphasized that larger studies and more sensitive genetic methods could change the estimated frequency by detecting lower-level or non-canonical variants. [4]

For patients, this body of work mainly affects understanding of diagnosis rather than day-to-day management. It helps clarify that targeted testing in certain clinical situations (like Sweet syndrome in older men, especially with macrocytic anemia) can uncover VEXAS that might otherwise be missed, while broad screening in MDS may depend heavily on which genetic test is used and how sensitive it is. What remains uncertain is the true rate of UBA1 mutations across different MDS populations and how often low-level mutations contribute to symptoms, which is why these results are best seen as a step toward better case-finding rather than a final answer. [3] [4]

This month, case reports mostly broadened the lived reality of VEXAS rather than changing big-picture conclusions. Several reports showed how VEXAS can first look like other diseases (such as rheumatoid arthritis-associated lung disease or isolated skin inflammation) until UBA1 testing and bone marrow findings clarify the diagnosis. Other reports highlighted that both the disease and its immune-suppressing treatments can be complicated by infections, and that responses can differ across organs, with some symptoms improving while anemia or lung disease persists. [5] [6] [7] [8] [9] [10] [11]

Two case reports added detail on treatment pathways that included azacitidine after other approaches did not fully control symptoms. One patient with VEXAS and MDS in Lebanon was reported to reach clinical and blood-count remission with transfusion independence after many cycles of azacitidine, following limited benefit from steroids and other immune drugs. Another older patient was reported to have more stable inflammatory markers and fewer hospitalizations after ruxolitinib followed by azacitidine, even though anemia persisted. [8] [7]

Several reports underlined diagnostic clues and the range of organ involvement. One patient with rheumatoid arthritis, MDS, and interstitial lung disease was ultimately found to have VEXAS through UBA1 testing after steroids did not help, illustrating overlap with other inflammatory lung conditions. Another report emphasized lab-based recognition using macrocytic anemia, high inflammation markers, and bone marrow vacuoles to prompt genetic testing, though the patient later developed lung cancer during follow-up. [10] [9]

Two case reports focused on less common but patient-important complications. One described ophthalmic artery vasculitis with optic perineuritis (inflammation around the optic nerve) that improved rapidly after high-dose steroids and then tocilizumab, suggesting VEXAS can involve eye blood vessels in ways that need urgent recognition. Another described cryptococcal meningitis occurring while a patient was on chronic steroids and ruxolitinib, with successful outcome after prolonged antifungal therapy, reminding readers that opportunistic infections can occur in heavily immune-suppressed situations. [5] [6]

A final case described a first genetically confirmed report from Tunisia, showing broad multisystem inflammation and cytopenias with a UBA1 p.Met41Thr mutation. The patient improved quickly on high-dose steroids but had infectious complications and relapse during tapering, echoing the larger observational message that steroid responses can be real but hard to sustain safely. [11]

For patients and caregivers, case reports are early signals rather than proof, but they can be helpful for recognition. This month they broadened what VEXAS can look like (including eye vessel inflammation and optic nerve sheath inflammation) and highlighted that serious infections can occur in the setting of prolonged immune suppression. They also added more real-world examples where azacitidine was reported to improve inflammatory symptoms and sometimes transfusion needs, while some problems like anemia or lung disease may persist. What remains uncertain is how often these presentations occur and which treatments work best across the wider VEXAS population, because single-patient experiences may not apply to others. [5] [6] [7] [8] [9] [10] [11]

Across cohort descriptions from different regions, the clinical picture of VEXAS looked consistent: many patients had macrocytic anemia, other low blood counts, and bone marrow vacuoles alongside multi-organ inflammation. These cohorts also continued to explore whether specific UBA1 variants line up with different outcomes, but the signals are still early because patient numbers are small and follow-up is limited. What became clearer this month is that different centers keep seeing similar core blood and bone marrow findings, while details like co-mutations and organ involvement vary from person to person. [12] [13] [1]

In a Chinese single-center series of 16 men identified among hematology patients, all had cytopenias and most had macrocytic anemia, with bone marrow hypercellularity and vacuoles reported in many cases. Most carried canonical p.Met41 UBA1 variants, and several non-canonical variants were also found, alongside frequent co-mutations (for example in TET2 or DNMT3A) and elevated inflammatory cytokines (IL-6 and IL-10 in those tested). The report adds to the idea that VEXAS is often both an inflammatory condition and a bone marrow disorder, especially when MDS is present. [12]

An India-centered multicenter cohort of 11 men reported that all tested bone marrow samples showed cytoplasmic vacuolations and that p.Met41 variants were common. This cohort reported that p.Met41Val was linked with poorer overall survival, and that several patients were treatment-refractory in their experience, with multiple deaths within a few years of diagnosis. Because the cohort is small, this variant-outcome signal should be seen as a clue that needs confirmation, not a settled fact for individual prediction. [13]

For patients, these cohorts mainly add understanding of what doctors often find when VEXAS is present: macrocytic anemia, other low blood counts, and characteristic changes in the bone marrow are repeatedly reported across countries. They also help clarify why people with VEXAS are often followed by both inflammation and blood specialists, since many patients have overlapping inflammatory symptoms and bone marrow changes such as MDS. What remains uncertain is how reliably a specific UBA1 variant predicts an individual person's future, since the reported survival differences come from small groups and need confirmation in larger studies. [12] [13] [1]